ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues

November 29, 2013

Clinton Administration Issues Research Misconduct Policy.

December 8, 2000

CTEP Analyses Proposals For Changes In Cooperative Groups

April 25, 1986

FDA, Companies Fail To Collect COI Forms, Report Says

January 16, 2009

Senate confirms Crawford as FDA commissioner.

July 22, 2005

Full Clearinghouse To Meet; Members Reveal Interests In Evaluations

October 28, 1977